Related Experiment Video
Updated: Jan 30, 2026
05:12
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
3.8K
Antiarrhythmic therapy in atrial fibrillation
1Department of Pharmacology und Toxicology, Medical Faculty Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74, D-01307 Dresden. Ravens@rcs.urz.tu-dresden.de
Pharmacology & Therapeutics
|July 14, 2010
Summary
Current antiarrhythmic drugs for atrial fibrillation (AF) are ineffective and cause side effects. New drug targets focusing on ion channels and calcium handling in the atria are needed for better AF management.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Available antiarrhythmic drugs for atrial fibrillation (AF) exhibit limited efficacy and significant side effect profiles.
- Understanding the mechanisms of AF generation and maintenance is crucial for developing improved therapeutic strategies.
Purpose of the Study:
- To review current pathophysiological and therapeutic concepts of AF.
- To describe recently developed antiarrhythmic drugs and their mechanisms of action.
- To explore potential novel drug targets for AF treatment in remodelled atria.
Main Methods:
- Literature review of current pathophysiological and therapeutic concepts of AF.
- Analysis of recently developed antiarrhythmic drugs and their proposed pharmacological actions.
- Speculative discussion on putative targets for antiarrhythmic drug development.
Main Results:
- Current AF management strategies are suboptimal due to drug ineffectiveness and adverse effects.
- Novel therapeutic targets may involve atrial-selective ion channels, pathology-selective ion channels, gap junctions, and intracellular calcium handling proteins.
- Upstream therapies targeting arrhythmia risk factors represent another potential approach.
Conclusions:
- Developing new antiarrhythmic drugs with improved efficacy and safety is a critical unmet need.
- Targeting specific ion channels, calcium homeostasis, and upstream risk factors holds promise for future AF pharmacotherapy.
- Further research into the molecular mechanisms of AF is essential for identifying and validating new drug targets.
Related Concept Videos
03:03Amyloid Fibrils
11.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.9K
03:03Amyloid Fibrils
6.4K
No description available
6.4K
01:11Fibril-associated Collagen
3.4K
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.4K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.5K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.5K
00:59Gene Therapy
27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.9K